Chemo, PARPi, Endocrine Therapy: Addressing Resistance with New Weapons Available to Purchase

Abstract: Resistance to taxane chemotherapy, PARP inhibition, and endocrine-agent in ER-positive breast cancer, remains problematic, but new approaches are emerging. Dendrimer nanoparticles may allow more effective delivery of cabazitaxel, and two first-in-class candidate drugs targeting USP1 and KAT6A/B, respectively, appear safe, tolerable, and show encouraging activity.